Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

Amgen’s Uplizna Approved by FDA for IgG4-Related Disease

Fineline Cube Apr 8, 2025

US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the...

Company Drug

J&J’s Rybrevant SC Formulation Approved by EC for NSCLC Treatment

Fineline Cube Apr 8, 2025

The European Commission (EC) has approved the subcutaneous (SC) formulation of Johnson & Johnson’s (J&J,...

Company Deals

TJ Biopharma Partners with Biogen on Felzartamab Phase III Studies in China

Fineline Cube Apr 8, 2025

China-based TJ Biopharma has entered into an agreement with US-based Biogen Inc. (NASDAQ: BIIB) to...

Company Drug

J&J’s Darzalex SC Formulation Approved for Newly Diagnosed Multiple Myeloma

Fineline Cube Apr 8, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received clearance from the European...

Policy / Regulatory

Shenzhen Unveils Comprehensive Policy Package to Boost Biopharma Innovation

Fineline Cube Apr 8, 2025

Shenzhen has launched an ambitious policy package, “Several Measures to Support Pharmaceuticals and Medical Devices...

Company Drug

AIM Vaccine’s Serum-Free Rabies Vaccine Accepted for Review by NMPA

Fineline Cube Apr 8, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) announced that its market filing for a serum-free...

Company Drug

SinoMab BioScience’s SM17 Shows Promising Results in Phase Ib Atopic Dermatitis Study

Fineline Cube Apr 8, 2025

Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced positive results from the Phase...

Company Drug

Luye Pharma’s Toludesvenlafaxine Approved for Marketing in Macau

Fineline Cube Apr 8, 2025

China-based Luye Pharma Group (HKG: 2186) announced that its extended-release depression treatment, toludesvenlafaxine (LY03005), has...

Company Drug

Shanxi Yanghe Medical Technology Faces Production Halt Over GMP Violation

Fineline Cube Apr 8, 2025

China’s National Drug Alliance Procurement Office has imposed manufacturing suspensions on Shanxi Yanghe Pharmaceutical Technology’s...

Company Drug

Hansoh Pharmaceutical Secures Dual NMPA Approvals for Oncology Pipeline Expansion

Fineline Cube Apr 8, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving dual clinical trial approvals...

Company Drug

Huadong Medicine’s DR30206 Approved for Clinical Trials in Gastrointestinal Tumors

Fineline Cube Apr 8, 2025

China-based Huadong Medicine Co., Ltd. (SHE: 000963) announced that it has received clinical trial approval...

Policy / Regulatory

Beijing Unveils Measures to Accelerate Innovative Drug Development and Regulatory Efficiency

Fineline Cube Apr 8, 2025

The Beijing Municipal Medical Insurance Bureau, in collaboration with seven other bureaus, has released the...

Company Deals

Novo Nordisk Partners with Tencent Healthcare for Weight Management Initiative in China

Fineline Cube Apr 8, 2025

In alignment with China’s “Weight Management Year” initiative, Denmark-based Novo Nordisk A/S (NYSE: NVO) has...

Company Deals

Siemens Set to Acquire Dotmatics for $5.1 Billion to Boost Life Sciences R&D

Fineline Cube Apr 8, 2025

German industrial giant Siemens AG (ETR: SIE) has announced plans to acquire US-based Dotmatics, a...

Company Deals

Lynmou Medical Secures Series A Funding for Endoscope Expansion

Fineline Cube Apr 8, 2025

Lynmou Medical, a Hangzhou-based provider of soft endoscope solutions, has reportedly secured “tens of millions”...

Company Drug

Phanes Therapeutics Gains CDE Approval for Peluntamig Phase II Trial in SCLC and NEC

Fineline Cube Apr 8, 2025

Sino-US biotech Phanes Therapeutics Inc. announced receiving approval from the Center for Drug Evaluation (CDE)...

Company Deals

Hengrui Pharmaceuticals Licenses SHR7280 to Merck for Assisted Reproduction

Fineline Cube Apr 8, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has entered into a licensing agreement with...

Company Drug

Suzhou Ribo Life Science Completes Enrollment for Phase IIa Study of FXI-Targeted siRNA Drug RBD4059

Fineline Cube Apr 8, 2025

China-based Suzhou Ribo Life Science Co., Ltd announced the completion of subject enrollment for the...

Company Drug

Nanjing King-Friend Bio’s Biosimilar Victoza Approved by FDA

Fineline Cube Apr 7, 2025

China-based Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (SHA: 603707) announced that its Abbreviated New Drug...

Company Drug

Bio-Sincerity Pharma-tech Gains NMPA Approval for BIOS-0618 in Obstructive Sleep Apnea

Fineline Cube Apr 7, 2025

Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) has secured clinical trial approval from China’s National...

Posts pagination

1 … 235 236 237 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.